Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
WELCHOL vs LINZESS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Welchol (colesevelam) is a bile acid sequestrant. It binds to bile acids in the intestine, forming an insoluble complex that is excreted in the feces. This disrupts the enterohepatic circulation of bile acids, leading to increased hepatic conversion of cholesterol to bile acids, resulting in decreased serum low-density lipoprotein cholesterol (LDL-C). Additionally, colesevelam may improve glycemic control in type 2 diabetes by binding to bile acids, which alters farnesoid X receptor (FXR) and TGR5 signaling, leading to increased glucagon-like peptide-1 (GLP-1) secretion and improved insulin sensitivity.
Linaclotide is a guanylate cyclase-C (GC-C) agonist that activates GC-C on the luminal surface of intestinal epithelial cells, increasing intracellular cyclic guanosine monophosphate (c GMP) levels. Elevated c GMP stimulates chloride and bicarbonate secretion into the intestinal lumen, increasing fluid secretion and accelerating gastrointestinal transit. Additionally, it reduces visceral pain by decreasing activity of pain-sensing nerves.
Primary hyperlipidemia (Fredrickson type IIa and IIb) as monotherapy or in combination with an HMG-Co A reductase inhibitor (statin) to reduce LDL-C,Adjunctive therapy for heterozygous familial hypercholesterolemia in pediatric patients aged 10-17 years,Improvement of glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise
Treatment of irritable bowel syndrome with constipation (IBS-C) in adults,Treatment of chronic idiopathic constipation (CIC) in adults,Off-label: Treatment of constipation-predominant IBS in pediatric patients (limited data)
Adults: 625 mg to 1.875 g orally twice daily, with meals. Maximum 4.375 g/day.
72 mcg to 290 mcg orally once daily on an empty stomach at least 30 minutes before the first meal of the day.
Not applicable; colesevelam acts locally in the gastrointestinal tract and is not absorbed systemically. Terminal half-life is not measurable in conventional pharmacokinetic sense due to negligible systemic absorption.
Terminal half-life is 6.6 hours (range 4 – 12 h) in healthy subjects; not prolonged in renal or hepatic impairment.
Colesevelam is not absorbed systemically and therefore not metabolized by hepatic cytochrome P450 enzymes. It acts locally in the gastrointestinal tract and is excreted unchanged in the feces.
Linaclotide is minimally absorbed systemically and is metabolized within the gastrointestinal tract to its active peptide. No significant hepatic metabolism occurs; the primary route of elimination is fecal excretion as the active peptide.
Primarily fecal as unchanged drug (approximately 85%), with less than 0.5% renal excretion of absorbed drug; no biliary excretion due to non-absorbed nature.
Primarily fecal (95%) as intact drug; renal excretion accounts for <1%.
<0.1% (negligible systemic absorption results in minimal protein binding; colesevelam is a non-absorbed polymer).
Approximately 94% bound to human serum albumin.
Not applicable (colesevelam is not systemically absorbed; Vd cannot be determined and is clinically irrelevant).
Mean Vd is 4.4 L/kg, indicating extensive extravascular distribution into tissues.
Oral bioavailability <0.5% (negligible systemic absorption); drug acts locally in gastrointestinal tract.
Oral bioavailability is approximately 4% due to extensive first-pass metabolism and low systemic absorption.
No dose adjustment needed for renal impairment.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment or end-stage renal disease; use cautiously.
Not recommended in patients with bowel obstruction or severe hepatic impairment; no specific Child-Pugh guidelines.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended in severe hepatic impairment (Child-Pugh C) due to lack of data.
Not approved for use in pediatric patients.
For functional constipation in pediatric patients: 72 mcg orally once daily for ages 6-17 years. Safety and efficacy not established below 6 years.
No specific dose adjustment; use with caution due to potential constipation.
No specific dose adjustment; start at 72 mcg daily. Monitor for diarrhea and electrolyte disturbances, especially in patients >65 years.
None
WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE. Linaclose is contraindicated in pediatric patients up to 6 years of age. In young juvenile mice, linaclotide caused deaths due to dehydration; this risk was highest in mice less than 3 weeks of age (approximately equivalent to human pediatric patients less than 2 years of age). Use LINZESS in pediatric patients from 6 to less than 18 years of age only for the treatment of functional constipation (FC) and after evaluating the risk of dehydration and ensuring adequate fluid intake.
May increase serum triglycerides; use with caution in patients with hypertriglyceridemia, particularly when triglyceride levels exceed 300 mg/d L, as it may cause severe hypertriglyceridemia and pancreatitis.,May decrease absorption of fat-soluble vitamins (A, D, E, K) and folic acid; monitor and consider supplementation if necessary.,May cause gastrointestinal adverse effects such as constipation, dyspepsia, and abdominal pain; patients should be advised to increase fluid and fiber intake.,May reduce absorption of orally administered drugs; administer other medications at least 4 hours before Welchol or consider separating by longer intervals.,Use with caution in patients with swallowing disorders or gastrointestinal motility disorders.,Not recommended for patients with pre-existing hypertriglyceridemia (triglycerides >500 mg/d L) due to risk of severe elevation.
Risk of serious dehydration in pediatric patients less than 2 years of age; contraindicated in patients up to 6 years of age.,Diarrhea: May cause severe diarrhea, especially during the first few weeks of treatment; if severe, discontinue use and rehydrate.,Do not use in patients with known or suspected mechanical gastrointestinal obstruction.
History of hypersensitivity to colesevelam or any component of the formulation,Bowel obstruction,Serum triglyceride level >500 mg/d L
Pediatric patients up to 6 years of age (risk of serious dehydration).,Known or suspected mechanical gastrointestinal obstruction.,Hypersensitivity to linaclotide or any component of the formulation.
Take with meals to enhance binding of bile acids. Avoid high-fat meals if triglycerides elevated. No specific food restrictions beyond general healthy diet.
Take on an empty stomach; avoid taking with food as food reduces absorption and efficacy.
Welchol (colesevelam) is a bile acid sequestrant. In animal studies, no evidence of teratogenicity was observed at doses up to 3 times the human dose. Human data are limited. The drug is not absorbed systemically, so fetal exposure is negligible. However, it may reduce absorption of fat-soluble vitamins (A, D, E, K), which are essential for fetal development. Insufficient vitamin K can cause neonatal coagulopathy. Therefore, potential risk of fetal harm is low but theoretical if maternal vitamin deficiency occurs. FDA Pregnancy Category B.
Linzess (linaclotide) is a guanylate cyclase-C agonist. Animal studies (rats, rabbits) at doses up to 800 mcg/kg/day showed no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. Based on animal data, the risk of major birth defects is low, but due to lack of human data, use only if clearly needed. First trimester: No known specific risk. Second and third trimesters: No known specific risk. No placental transfer data available; linaclotide is a large peptide with minimal systemic absorption, likely negligible fetal exposure.
Colesevelam is not absorbed systemically and is not expected to be excreted into breast milk. No human studies are available. The M/P ratio is unknown but likely extremely low due to lack of absorption. Caution is advised, but risk to nursing infant is minimal. Monitor infant for signs of vitamin deficiency if mother is on long-term therapy.
No human data on linaclotide excretion in breast milk. Animal studies show low levels in rat milk with M/P ratio approximately 0.1-0.2. Due to minimal systemic absorption after oral administration, excretion into human milk is expected to be negligible. However, caution is advised. No adverse effects observed in nursing pups in animal studies. Consider benefits vs risks.
No pharmacokinetic changes are reported for colesevelam in pregnancy as it is not absorbed. Standard dosing may be used, but ensure adequate supplementation of fat-soluble vitamins, especially vitamins A, D, E, and K. Dose adjustments are not required based on pregnancy status alone. Monitor for constipation, which may be exacerbated in pregnancy.
No pharmacokinetic data on linaclotide in pregnancy. Due to minimal systemic absorption, significant pharmacokinetic changes are unlikely. No dose adjustment recommended in pregnancy. Standard dosing for chronic idiopathic constipation or irritable bowel syndrome with constipation (145 mcg or 290 mcg once daily) may be used if clinically indicated. Use caution in third trimester if risk of dehydration due to diarrhea.
Administer Welchol at least 4 hours after other medications to avoid binding and reducing absorption. Monitor LDL-C reduction at 4-6 weeks; may increase triglycerides. Contraindicated in history of hypertriglyceridemia-induced pancreatitis.
Initiate at 290 mcg daily for IBS-C; 145 mcg daily for CIC; take on empty stomach at least 30 minutes before first meal; capsules must be swallowed whole; clinical response may take 2-4 weeks; contraindicated in patients with known or suspected mechanical GI obstruction; avoid in pediatric patients less than 2 years of age due to risk of serious diarrhea and dehydration.
Take Welchol with a meal and plenty of water.,Take other medications at least 4 hours before or after Welchol.,Do not crush or chew the tablets; swallow whole.,May cause constipation; increase fluid and fiber intake.,Report severe stomach pain or triglyceridemia symptoms.
Take LINZESS at least 30 minutes before your first meal of the day on an empty stomach.,Swallow capsules whole; do not crush, chew, or open them.,Do not take LINZESS if you have a bowel blockage (intestinal obstruction).,Common side effects include diarrhea, abdominal pain, and gas; severe diarrhea may occur, especially in children under 2 years.,Tell your doctor if you have severe or persistent diarrhea, or if you experience symptoms of dehydration.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about WELCHOL vs LINZESS, answered by our medical review team.
WELCHOL is a Bile Acid Sequestrant that works by Welchol (colesevelam) is a bile acid sequestrant. It binds to bile acids in the intestine, forming an insoluble complex that is excreted in the feces. This disrupts the enterohepatic circulation of bile acids, leading to increased hepatic conversion of cholesterol to bile acids, resulting in decreased serum low-density lipoprotein cholesterol (LDL-C). Additionally, colesevelam may improve glycemic control in type 2 diabetes by binding to bile acids, which alters farnesoid X receptor (FXR) and TGR5 signaling, leading to increased glucagon-like peptide-1 (GLP-1) secretion and improved insulin sensitivity.. LINZESS is a Guanylate Cyclase-C Agonist that works by Linaclotide is a guanylate cyclase-C (GC-C) agonist that activates GC-C on the luminal surface of intestinal epithelial cells, increasing intracellular cyclic guanosine monophosphate (c GMP) levels. Elevated c GMP stimulates chloride and bicarbonate secretion into the intestinal lumen, increasing fluid secretion and accelerating gastrointestinal transit. Additionally, it reduces visceral pain by decreasing activity of pain-sensing nerves.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between WELCHOL and LINZESS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of WELCHOL is: Adults: 625 mg to 1.875 g orally twice daily, with meals. Maximum 4.375 g/day.. The standard adult dose of LINZESS is: 72 mcg to 290 mcg orally once daily on an empty stomach at least 30 minutes before the first meal of the day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between WELCHOL and LINZESS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. WELCHOL is classified as Category C. Welchol (colesevelam) is a bile acid sequestrant. In animal studies, no evidence of teratogenicity was observed at doses up to 3 times the human dose. Human data are limited. The d. LINZESS is classified as Category C. Linzess (linaclotide) is a guanylate cyclase-C agonist. Animal studies (rats, rabbits) at doses up to 800 mcg/kg/day showed no evidence of teratogenicity. There are no adequate and. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.